Clinical Trial Update: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD [Phase 3]

View source ↗

Summary

A Phase 3 study comparing the efficacy, safety and tolerability of a fixed-dose triple combination CHF 5993 versus a fixed-dose dual combination CHF 1535 in adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Exacerbation of Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 1535
• CHF 5993

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD, COPD Exacerbation | Phase 3 | Status: COMPLETED